Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00258869|
Recruitment Status : Unknown
Verified January 2009 by National Center for Genome Resources.
Recruitment status was: Recruiting
First Posted : November 28, 2005
Last Update Posted : November 9, 2010
|First Submitted Date||November 23, 2005|
|First Posted Date||November 28, 2005|
|Last Update Posted Date||November 9, 2010|
|Study Start Date||December 2005|
|Estimated Primary Completion Date||July 2010 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures
|Original Primary Outcome Measures||Not Provided|
|Change History||Complete list of historical versions of study NCT00258869 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures
|Original Secondary Outcome Measures||Not Provided|
|Current Other Outcome Measures||Not Provided|
|Original Other Outcome Measures||Not Provided|
|Brief Title||Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests|
|Official Title||Plasma Protein Biomarker Based Diagnostics of Outcome in Sepsis & CAP|
We propose to develop novel diagnostic tests for severe sepsis and community acquired pneumonia (CAP). This program, entitled Community Acquired Pneumonia & Sepsis Outcome Diagnostics (CAPSOD), is a multidisciplinary collaboration involving investigators at six organizations: NCGR; Duke University Medical Center, Durham, NC; Henry Ford Hospital, Detroit, MI; Eli Lilly and Company, Indianapolis, IN; Indiana Centers for Applied Protein Sciences, Indianapolis, IN; and ProSanos Corp., La Jolla, CA.
In the United States, Community Acquired Pneumonia is the sixth leading cause of death and the number one cause of death from infectious diseases. Of the 5.6 million annual cases of CAP, 1.1 million require hospitalization for intensive therapy. Sepsis, commonly known as blood poisoning or bloodstream infection, is the tenth leading cause of death in the US and the number one cause of death in non-cardiac intensive care units. Incidence of sepsis is increasing by 9% each year and mortality rates vary between 25 and 50%. Cost to the US healthcare system exceeds $20 billion each year.
In patients with suspected sepsis or early CAP, rapid identification of patients who will develop severe sepsis or CAP is critical for effective management and positive outcome. The CAPSOD study is designed to identify novel tests for early diagnosis of severe sepsis and CAP. When performed in patients at the earliest stages of disease, these tests will have prognostic value, rapidly identifying those who will have poor outcomes or complicated courses.
CAPSOD will prospectively enroll patients with sepsis and CAP at Duke University Medical Center and Henry Ford Hospital. The study will use advanced bioinformatic, metabolomic, proteomic and mRNA sequencing technologies to identify specific protein changes, or biomarkers, in patient blood samples that predict outcome in sepsis and CAP. Development of biomarker-based tests will permit patient selection for appropriate disposition, such as the intensive care unit, and use of intensive medical therapies, thereby reducing mortality and increasing effectiveness of resource allocation.
3 interdependent aims are proposed to discover and initiate development of novel, in vitro diagnostic tests (IVD) for severe sepsis (SS) and community acquired pneumonia (CAP).
Specific Aim 1: Discovery and initial development of an IVD for early diagnosis of severe sepsis.
In patients with suspected sepsis, early, accurate identification of patients who will develop organ dysfunction (SS) is critical for effective management and positive outcome. While the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions provide a clinical guide to identifying patients who have SS, we propose to develop a rapid, point-of-care (POC) IVD for early diagnosis of SS. The basis of the proposed IVD will be the measurement of several, host response, plasma proteins. When performed in patients at the earliest stage of sepsis, this test will have prognostic value, rapidly identifying patients who will have poor outcomes or complicated courses.
Availability of this IVD will enable patient selection for appropriate disposition, such as the intensive care unit (ICU), and use of medical therapies, such as early goal-directed therapy (EGDT), thereby reducing mortality and increasing effectiveness of resource allocation. A considerable literature exists of host plasma protein changes during sepsis. Furthermore, in preliminary studies measuring more than 100 host proteins in blood of over 300 patients with SS, we have identified a number of candidate biomarkers of SS. We propose to inventory, replicate and validate the utility of these biomarkers of SS, and to identify novel plasma biomarkers of SS, through literature review and a prospective clinical study employing 2 proteomic technologies (mass spectrometry and multiplexed immunoassays), mass spectrometry-based plasma metabolomics and sequencing of mRNA derived from peripheral blood lymphocytes. We intend to enroll 1200 patients with sepsis (evidence of infection and 2 or more criteria of the systemic inflammatory response syndrome, SIRS) at 3 US tertiary care hospitals and emergency departments (ED), and to monitor their course both by established clinical severity indices (Acute Physiology and Chronic Health Evaluation [APACHE II] and Pneumonia Patient Outcomes Research Team [PORT]scores, and metabolic endpoints such as lactate, base deficit and pH) and ascertainment of complicating events (such as SS, septic shock, acute renal failure (ARF), acute respiratory distress syndrome (ARDS),disseminated intravascular coagulopathy (DIC) and death). It is anticipated that approximately 60% of the patients will develop SS.
Data will be stored in an anonymized, encrypted, web-based patient registry. Bivariable analyses will be performed to identify and validate biomarker differences between groups. Furthermore, we intend to perform predictive modeling using multivariable analyses of the validated biomarkers and derive a biomarker panel and algorithm for early diagnosis of SS. The predictive value of the biomarker panel for early diagnosis of SS will be compared with established prognostic indices, such as metabolic endpoints and APACHE II score. Novel biomarkers of severe CAP will be identified by mass spectrometry of patient EDTA plasma samples. Subject to availability of multiplexed immunoassays, some of these biomarkers will be replicated by immunoassay in the same samples.
During the period of award, a plan for IVD development of the biomarker panel for early diagnosis of SS will be developed. This is anticipated to involve assay optimization and transfer to an existing, validated IVD platform, FDA-regulated IVD development processes, and incorporation of the IVD into an intensive treatment algorithm. The proposed IVD will be an oligoplex assay performed on a single blood sample using immunoassays on an established diagnostic platform with time-to-first result of less than 30 minutes and capable of use in a POC setting, such as an ED or ICU.
Specific Aim 2: Biomarker development for early differentiation of poor outcome in CAP Complications of CAP, including respiratory failure, other organ system failure and severe sepsis, are major determinants of morbidity and mortality. At time of presentation with CAP, accurate identification of patients who will have a complicated course or poor outcome is critical for effective management and positive outcome. In parallel with Specific Aim 1, we propose to identify biomarkers for early diagnosis/prognosis of poor outcome in patients with CAP ("severe CAP"). The biomarkers will be several, host response, plasma proteins that differentiate mild and severe CAP. Early diagnosis of severe CAP will enable patient selection for hospitalization, thereby reducing mortality and increasing effectiveness of resource allocation.
It is anticipated that approximately 33% of the patients enrolled in the Specific Aim 1 clinical study (evidence of infection and two or more SIRS criteria) will have CAP as the underlying infection causing sepsis. Furthermore, it is anticipated that approximately 25% of these CAP patients will develop severe CAP. Specific aim 2 proposes a secondary, separate analysis of all patients enrolled in the Specific Aim 1 clinical study who have CAP in order to identify biomarkers for early diagnosis of severe CAP. We propose to inventory existing candidate biomarkers of severe CAP through literature review. Furthermore, we propose to validate the utility of some of these biomarkers, and to identify a number of novel biomarkers of severe CAP through analysis of the subset of patients in the prospective clinical study who have CAP and employing 2 proteomic technologies (mass spectrometry and multiplexed immunoassays), mass spectrometry-based plasma metabolomics and sequencing of mRNA derived from peripheral blood lymphocytes. Bivariable analyses will be performed to identify plasma biomarker differences between mild and severe CAP. Multivariable analyses will be performed in order to derive a plasma biomarker panel and algorithm for early diagnosis of severe CAP. The biomarker panel for early diagnosis of severe CAP will be compared with established prognostic indices, such as PORT score. Novel biomarkers of severe CAP will be identified by mass spectrometry of patient EDTA plasma samples.
Subject to availability of multiplexed immunoassays, some of these biomarkers will be replicated by immunoassay in the same samples.
During the period of award, a plan for panel validation and IVD development for early diagnosis of severe CAP will be developed. The latter is anticipated to involve assay optimization and transfer to an existing, validated IVD platform, FDA regulated IVD development processes, and incorporation of the IVD into an intensive treatment algorithm. The proposed IVD will be an oligoplex assay performed on a single blood sample using immunoassays on an established diagnostic platform with time-to-first result of less than 30 minutes and capable of use in a POC setting, such as an ED or ICU. This is anticipated to be a product line extension of the SS IVD.
Specific Aim 3: Biomarker development for early differentiation of sepsis and CAP pathogens Currently, initial antimicrobial treatment of sepsis and CAP is empiric. Common etiologic agents in sepsis are gram-positive bacteria (Staphylococcus spp. and Streptococcus spp.), gram-negative bacteria (e.g., Escherichia coli, Klebsiella spp., and Enterobacter spp.), and fungi (Candida spp.). Common etiologic agents in CAP are Streptococcus pneumoniae, Legionella pneumophila, Mycoplasma spp., and viruses. The ability to distinguish these pathogens at time of presentation of sepsis or CAP would potentially allow more targeted rather than broad-spectrum initial therapy. Earlier administration of appropriate antimicrobials would lower patient management cost associated with ineffective therapy and lessen likelihood of antibiotic resistance. We propose to identify host biomarkers for early differentiation of up to 4 common etiologic agents in sepsis and CAP. Our preliminary studies have established proof-of-concept for differentiation between classes of pathogens in sepsis based on specific differences in soluble host proteins in a blood sample. Based on our preliminary studies, it is anticipated that approximately 25% of patients in the Specific Aim 1 clinical study will have a positive blood culture. At least 33 of these patients are anticipated to have S. aureus bacteremia and 20 gram negative bacteremia. Specific Aim 3 proposes to compare plasma samples from patients with S. aureus and gram negative bacteremia in order to identify host biomarkers for early differentiation of specific class agent in sepsis. As in specific aims 1 and 2, bivariable and multivariable analyses of biomarkers is proposed to develop a biomarker panel for early differentiation of staphylococcal and gram-negative sepsis. Similar analysis is proposed to differentiate CAP pathogens. However, given the absence of a high-sensitivity, gold-standard method for determination of causal pathogen in CAP, Specific Aim 3 proposes the more conservative goal of differentiating pneumococcal CAP from atypical CAP based on quantitative differences in host blood biomarkers. The pneumococcal CAP group will be selected from the clinical studydataset based on rigorous criteria: S. pneumoniae from blood or sputum culture or detection of pneumococcal antigen in urine, clinical evidence of CAP and typical (lobar consolidation) chest radiograph. The nonpneumococcal CAP group will be determined by negative pneumococcal cultures and urine antigen, clinical evidence of CAP, and an atypical chest radiograph. It is anticipated that at least 20 patients (15% of the 133 with CAP) will have confirmed pneumococcal CAP and 40 patients (30%) atypical, non-pneumococcal CAP. Biomarkers for differentiation of i. S. aureus bacteremia from gram-negative bacteremia, and ii. pneumococcal CAP from atypical CAP, will be identified by mass spectrometry of patient EDTA plasma samples. Subject to availability of multiplexed immunoassays, some of these biomarkers will be replicated by immunoassay in the same samples. It should be noted that given budget-imposed reduction in patient enrollment of one third from that originally proposed, we are uncertain that sufficient patients will be enrolled for all Specific Aim 3 analyses to be meaningful. We propose to evaluate the group sizes of enrolled patients by specific class agent in order to select two specific comparisons between sepsis and CAP pathogens that are of sufficient size to permit meaningful analysis.
Validation and development of these biomarkers into biomarker panels and rapid, POC, IVD for early differentiation of pathogen in sepsis and CAP is intended, but is beyond the scope of the present proposal. A product line extension of the SS IVD is envisaged. Like the test for early diagnosis of SS, the IVD(s) for early differentiation of CAP and sepsis pathogens will be oligoplex assay(s) performed on single blood sample(s) using immunoassays or other analyte assays.
|Study Design||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration||Not Provided|
|Biospecimen||Retention: Samples With DNA
PaxGene whole blood tubes (RNA and DNA), EDTA plasma, serum (subset), microbiologic isolates
|Sampling Method||Non-Probability Sample|
|Study Population||Emergency department patients > 6 years of age|
Emergency department patients with sepsis
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status||Unknown status|
|Estimated Study Completion Date||July 2010|
|Estimated Primary Completion Date||July 2010 (Final data collection date for primary outcome measure)|
1. Patient has known or acute infection or suspected infection AND patient must meet at least 2 of the following 4 criteria to be enrolled
|Ages||6 Years and older (Child, Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries||United States|
|Removed Location Countries|
|Other Study ID Numbers||0001
U01AI066569 ( U.S. NIH Grant/Contract )
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Stephen F. Kingsmore, President, National Center for Genome Resources|
|Study Sponsor||National Center for Genome Resources|
|PRS Account||National Center for Genome Resources|
|Verification Date||January 2009|